Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2009

XTL Obtains Rights to Use Bio-GAL's Recombinant Erythropoietin as a Myeloma Treatment

XTL Obtains Rights to Use Bio-GAL's Recombinant Erythropoietin as a Myeloma Treatment

XTL enters asset purchase agreement with Bio-GAL

  • XTL Biopharmaceuticals entered into an asset purchase agreement with Bio-GAL for the rights to a use patent on the recombinant erythropoietin, rHuEPO, to develop a treatment for multiple myeloma. XTL will issue ordinary shares just under 50% of the current issued and outstanding share capital of the company.

    Bio-GAL will receive a milestone payment of $10 million upon the successful completion of a Phase II trial and 1% in royalties on net sales of the product. XTL's board of directors reserves the right to issue additional ordinary shares to Bio-GAL in lieu of the milestone payment.

    The transaction is expected to close in the second or third quarter. Erythropoietin is used as a therapeutic agent in kidney disease and cancer-related anemia. It is produced by recombinant DNA technology in mammalian cell culture.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »